By CapitalSnitch Research Desk · updated Oct 11, 2026 · data from SEC filings and official Congress disclosures
Over 12 months, Ascendis Pharma A/S saw more selling than buying from its insiders — purchases of about $777,000 against sales of $5.5 million.
Biggest single buyer: BIENAIME JEAN JACQUES, Director, with roughly $270,000. Notably, at least one C-suite executive was among the buyers.
Quarter by quarter: 2 quarters in a row of net selling by insiders. Insiders bought in 2 of the last 7 full quarters. 301 investment managers listed ASND in their latest 13F filings (Q2 2026); more funds bought than sold.
Are insiders buying or selling ASND stock?
In the last 12 months Ascendis Pharma A/S insiders made open-market purchases worth about $777,000 and sales worth about $5.5 million. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
When was the last insider trade in ASND?
The most recent open-market insider trade in ASND was filed on 2026-09-09.
How many institutions own ASND?
301 investment managers reported holding ASND in SEC Form 13F filings for Q2 2026.
Has any member of Congress traded ASND?
No congressional trades in ASND were reported in the past two years. The full list is free on CapitalSnitch.
Free weekly email: the week's biggest insider buys and Congress trades, every Monday. No spam, one-click unsubscribe.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1).
Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).